

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3815847

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MEDICENNA THERAPEUTICS PTE LTD	12/31/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	MEDICENNA THERAPEUTICS, INC.
<b>Street Address:</b>	1500 WEST GEORGIA STREET
<b>Internal Address:</b>	SUITE 1300
<b>City:</b>	VANCOUVER
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	V6G 2Z6
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15024787
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(415)442-1001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(415) 442-1000
<b>Email:</b>	llim@morganlewis.com
<b>Correspondent Name:</b>	BRETT A. LOVEJOY
<b>Address Line 1:</b>	ONE MARKET, SPEAR STREET TOWER
<b>Address Line 2:</b>	MORGAN, LEWIS & BOCKIUS LLP
<b>Address Line 4:</b>	SAN FRANCISCO, CALIFORNIA 94105
<b>ATTORNEY DOCKET NUMBER:</b>	000718-5032-US
<b>NAME OF SUBMITTER:</b>	LINDA LIM
<b>SIGNATURE:</b>	/Linda Lim/
<b>DATE SIGNED:</b>	04/05/2016
<b>Total Attachments: 2</b>	
source=000718-5032-US - Assignment - Medicenna Therapeutics Pte Ltd to Medicenna Therapeutics Inc#page1.tif	
source=000718-5032-US - Assignment - Medicenna Therapeutics Pte Ltd to Medicenna Therapeutics Inc#page2.tif	

## ASSIGNMENT AGREEMENT

THIS ASSIGNMENT AGREEMENT effective December 31, 2014, is made by and between:

MEDICENNA THERAPEUTICS PTE LTD, having an address of WCEGA Tower, 14-74, 21 Bukit Batok Crescent Singapore 238991, Singapore, (the "Assignor");

AND:

MEDICENNA THERAPEUTICS, INC., having a place of business at 1500 West Georgia Street, Suite 1300, Vancouver, BC V6G 2Z6, Canada, (the "Assignee").

WHEREAS the Assignor, has invented certain new and useful improvements as described in the patent application entitled:

### INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOF

for which a United States provisional patent application no. 61/881,930 was filed on September 24, 2013 and a PCT patent application no. PCT/CA2014/050916 was filed on September 24, 2014 (the "Applications");

WHEREAS the Assignee has acquired from the Assignor the whole right, title and interest for the United States, Canada and all other countries in and to the invention and in and to any Letters Patent that may be obtained therefor, and in and to the Applications, and in and to any applications claiming priority therefrom or the benefit thereof, and any national phase entries and related divisionals, continuations, reissues and extensions of such applications.

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt of all of which is hereby acknowledged, the Assignor confirms that they have sold, assigned and transferred and do hereby sell, assign and transfer unto the Assignee, the full and exclusive right to the Applications in the United States, Canada and all other countries, the entire right, title and interest in and to any and all Letters Patent which may be granted therefor, and the entire right, title and interest in and to the Applications, and in and to any applications claiming priority therefrom or the benefit thereof, and any national phase entries and related divisionals, continuations, reissues and extensions of such applications.



The Assignor agrees that they will, without further consideration, do all such things and execute all such documents as may be necessary or desirable to obtain and maintain patents for the Applications, and in and to any applications claiming priority therefrom or the benefit thereof, and any national phases entries and related divisionals, continuations, reissues and extensions of such applications, and for additions and modifications thereto in any and all countries, and to vest title thereto in the Assignee, their successors, assigns and legal representatives or nominees.

The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States of America, the Canadian Intellectual Property Office and any official of any country or countries foreign to the United States and to Canada whose duty it is to issue patents on applications as aforesaid, to issue any said Letters Patent to the Assignee of the entire right, title and interest in and to the same, for their sole use and benefit, and for the use and benefit of their successors and assigns, to the full end of the term for which the Letters Patent may be granted as fully and entirely as the same would have been held by the Assignor had this assignment and sale not been made.

This Assignment may be signed in as many counterparts as may be necessary, and may be signed by facsimile or other means of electronic communication producing a printed copy, each of which so signed shall be deemed to be an original, and such counterparts together shall constitute one and the same instrument and notwithstanding the date of execution shall be deemed to bear the date set forth above.


The Assignor and the Assignee hereby authorize the firm of Fasken Martineau DuMoulin, whose full post office address is 2900 – 550 Burrard Street, Vancouver, British Columbia V6C 0A3, Canada, to correct errors in this Assignment, or to insert any further identification or other information necessary or desirable to make this Assignment suitable for recordal in the Patent Office.

IN TESTIMONY WHEREOF, the parties have hereunto set their hands.

WITNESSED BY	)	MEDICENNA THERAPEUTICS PTE LTD
Signature: <u></u>	)	Signature: <u></u>
Name: <u>SHAFIQUE FUDA</u>	)	Print Name: <u>FATAR MERCHANT</u>
Address: <u>4080 Goldie Court</u>	)	Title: <u>DIRECTOR</u>
<u>North Vancouver, BC, V7G 2P4</u>	)	Date: <u>31 December 2014</u>

This Assignment is accepted by MEDICENNA THERAPEUTICS, INC.

MEDICENNA THERAPEUTICS, INC.

  
Signature of Authorized Signatory

Title: PRESIDENT & CEO

Date: 31 December 2014